Hepatitis, Alcoholic Clinical Trial
Official title:
Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN).
The primary objective of this study is to determine the prevalence of AH in addition to its clinical characteristics and in-hospital mortality of patients that are hospitalized for AH in different hospitals across Latin American countries This study is carried out in different health centers throughout America, with all the countries belonging to the Latin American Association for the study of liver diseases (ALEH) more Canada and United States This would allow us to better understand the epidemiology of AH in our region and thus implement prevention measures with more solid data. Importantly, this would allow us to optimize therapeutic measures
This study is sponsored and organized by the "group Latin American of interest special in the
study of the disease hepatic Alcohol" (ALEH-GLEHA), belonging to the Latin American
Association for the study of the hepatic illnesses (ALEH), which is an association non-profit
that has nearly 1,000 members from most of the countries of Latin America.
All patients admitted to the hospital with suspected alcoholic hepatitis will be evaluated to
see if they can be included in the study. Patients will be enrolled according with the
inclusion and exclusion criteria.
The investigators will take a blood sample to be analyzed as part of the necessary data
record, for the study of genes and identification of proteins involved in the development,
evolution and prognosis of alcoholic hepatitis.
If the medical doctor had instructed to perform a liver biopsy, voluntarily the investigators
will ask to participants donate a small share of the surplus of histological sample To
achieve this, it is necessary to generate a data bank of clinical information and biological
samples (blood, urine, bile, stools, salivary sample or tissue samples) that allows studying
the various factors involved in the development and prognosis of this disease in the
countries of the Americas.
The investigators will make a clinical follow-up for a year, consisting of phone calls to
complete a questionnaire about participant's health. These calls will be made in month 1, 3,
6 and 12 subsequent to participant's hospital discharge.
The data collected are identified by a code and only the study physicians can correlate the
data with the participants and medical history, so the participant's identity will not be
shared.
There is no financial compensation associated with the study
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00205049 -
Pentoxifylline for Acute Alcoholic Hepatitis (AAH)
|
Phase 1 | |
| Completed |
NCT00913757 -
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
|
||
| Active, not recruiting |
NCT02404636 -
Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis
|
N/A | |
| Completed |
NCT01968382 -
Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis
|
Phase 2 | |
| Recruiting |
NCT02024295 -
Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis
|
Phase 4 | |
| Enrolling by invitation |
NCT04234139 -
Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
|